While cosmetic enhancements, for example fillers and Botox, will still be (unfortunately) considered taboo in today’s society, surprisingly, the amount of people getting work done goes up and up. Actually, in 2015, Americans were injected more than 6.6 million times, in accordance with the American Society for Aesthetic Cosmetic Surgery, which is actually a whopping forty percent increase from five-years ago. And now, those 6 million and counting have one more method to consider when booking their next appointment, as the FDA just approved a brand name-new filler: Juvéderm Vollure XC.
Allergan, the pharmaceutical company that owns Juvéderm, just announced its newest juvederm los angeles, Juvéderm Vollure XC, that has been approved for the correction of “moderate to severe facial wrinkles and folds, such as nasolabial folds,” in accordance with an announcement made by the company. What’s more is the fact this filler, created for those over 21, is said to last so long as 18 months – a complete year more than other injectables on the market.
In a clinical trial to the injectable, 59 percent of participants saw improvement in smile lines throughout the mouth for as much as 18 months, and at the same time, 82 percent of patients said they were pleased with results at 6 months, while 68 percent were pleased at eight months. Sounds great, but how will it work? We tapped The Big Apple dermatologist Joshua Zeichner to get more in the technology behind the filler.
Juvéderm Vollure XC uses special technology, known as Vycross – that is also employed in Juvéderm Voluma XC and Juvéderm Volbella XC – to hold the hyaluronic acid together into a cohesive gel, which will keep it intact after it’s injected into the skin, explains Zeichner. “Vollure XC’s Vycross technology links both high and low molecular-weight hyaluronic acid, while Juvederm’s Hylacross technology uses various degrees of cross-linking of mainly high molecular weight hyaluronic acid.”
In non-cosmetic surgeon speak, this means that the mix of high and low hyaluronic acid from the Vycross technology creates a more connected gel, which may be molded, effectively lifting sunken skin sitting above it. “Vollure sits for the reason that sweet spot where it can be firm enough to fill the line, but soft enough to go naturally with facial expression,” says Zeichner. Another major distinction between Juvéderm and the new Juvéderm Vollure XC is the fact that new formula produces minimal swelling, meaning shorter time to recover. “The gel may also keep going longer than other products, making it a greater value for your price and the requirement for fewer injection sessions,” says Zeichner.